Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10833210 | Molecular Genetics and Metabolism | 2013 | 7 Pages |
Abstract
We observed a mean annual change of the composite score of 0.04 in our cohort, indicating slower progression of neurological symptoms if compared with the natural history of the disease. The evidence of slower disease evolution in patients treated with Miglustat suits with previous data and here it is also emphasized by the comparison between disease progression in two early-infantile onset patients receiving different Miglustat dosages. Evaluation of the mean annual change for individual subgroups of patients evidenced minor values in juvenile patients, highlighting better response in such class of patients. Among individual neurological parameters, swallowing showed the minor mean annual change (0.02), indicating better response to therapy. We underline the importance of using a standardized disability scale to quantify and compare neurological features and their evolution over time.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Virginia Maria Ginocchio, Adele D'Amico, Enrico Bertini, Ferdinando Ceravolo, Andrea Dardis, Daniela Verrigni, Bruno Bembi, Carlo Dionisi-Vici, Federica Deodato,